Exelixis Inc. (EXEL)
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Top-Ranked Value Stocks With Discounted PEG Ratio to Buy
Five PEG-based stocks that fulfill our screening criteria are Genpact, MPLX, Exelixis, Paramount Global and H&R Block.
Why Exelixis (EXEL) Might be Well Poised for a Surge
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Exelixis Earnings Drive Share Growth
Oncology company Exelixis, Inc. (EXEL) reported better-than-expected results, driving big share gains.
3 Stocks to Buy for a Soft Landing, If There Is One
Recent economic data is reigniting talk about a soft landing for the economy. That means that the Federal Reserve's monetary policy regarding interest rates is neither too restrictive nor too loose.
4 Best Defensive Stocks For A Potential Soft Landing (SA Quant)
Investors are seeking stability amid the global market selloff in early August, sparked by weak jobs data and fears of an emergency interest rate cut by the Fed. Recession fears were ignited after the yield curve uninverted to cause speculation that the Fed could begin rate cuts in September. With many investors on the defense, and seeking safe-haven investments, staples, healthcare, and utilities have outperformed the market during six of the last seven U.S. recessions.
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue Trends
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Exelixis: sNDA Cabometyx Expansion Could Provide Revenue Boost
Exelixis, Inc. has a PDUFA date of April 3, 2025, set to decide whether Cabometyx should be approved for the treatment of patients with advanced pancreatic neuroendocrine tumors. U.S. net product revenues of Cabometyx grew by 16% quarter over quarter and a 7% year-over-year increase. Preliminary results from phase 3 STELLAR-303 study, using zanzalintinib in combination with Tecentriq to treat patients with metastatic refractory colorectal cancer that is not microsatellite instability-high or mismatch repair-deficient.
